Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11092129 | 0.74 | CSF1R (0.39) | KDM4EHSD17B10HPGDMAPTTSHR | |
| SCHEMBL8976268 | 0.74 | ALDH1A1 (0.44) | KDM4EHSD17B10HPGDALOX15RECQL | |
| SCHEMBL12043521 | 0.74 | CYP1A2 (0.44) | KDM4EHSD17B10MAPTCYP1A2TSHR | |
| SCHEMBL476813 | 0.74 | CYP1A2 (0.44) | KDM4EHSD17B10HPGDTDP1MAPT | |
| SCHEMBL658519 | 0.74 | NOS1 (0.39) | KDM4EHSD17B10MAPTCSF1RFLT1 | |
| SCHEMBL28176894 | 0.70 | ALDH1A1 (0.36) | HPGDMAPTALDH1A1MAOA | |
| SCHEMBL30412398 | 0.69 | CSF1R (0.33) | KDM4EHSD17B10MAPTCSF1RFLT1 | |
| SCHEMBL291713 | 0.69 | ALDH1A1 (0.42) | KDM4EHSD17B10HPGDALOX15TDP1 | |
| SCHEMBL13913276 | 0.69 | GABRA1 (0.39) | KDM4EHSD17B10HPGDMAPTCYP1A2 | |
| SCHEMBL28086993 | 0.69 | CYP2A6 (0.40) | KDM4EHSD17B10HPGDTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4189433-A | ADRENERGIC BLOCKING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | claimed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3526206-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-21 | — | — | EP | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2004043904-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043903-A1 | 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043931-A1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-0038458-A1 | 4-Hydroxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide, their salts, their preparation and their utilization | Dr. Karl Thomae GmbH (DE) | 1981-10-28 | — | — | EP | disclosed |
| US-4189433-A | ADRENERGIC BLOCKING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
| US-4189433-A | ADRENERGIC BLOCKING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
| US-4189433-A | ADRENERGIC BLOCKING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
| US-4168317-A | CARDIOVASCULAR DISORDERS, ANTIARRYTHMIA | BASF AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
| US-4168317-A | CARDIOVASCULAR DISORDERS, ANTIARRYTHMIA | BASF AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
| US-4168317-A | CARDIOVASCULAR DISORDERS, ANTIARRYTHMIA | BASF AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | KDM4E 2350/4885MAPKAPK2 4625/4885HSD17B10 466/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | KDM4E 2350/4885MAPKAPK2 4625/4885HSD17B10 466/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | KDM4E 3110/4885MAPKAPK2 338/4885HSD17B10 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.